Compare Cytokinetics Inc (CYTK) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Gap Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Gap Inc trades at $23.33 (market cap $8.29B). The key difference: Cytokinetics Inc and Gap Inc are close in size by market cap, and Gap Inc pays a 2.96% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Gap Inc for 37 Days on average.
| CYTK | GAP | |
|---|---|---|
Market Cap | $8.50B | $8.29B |
Volume | 2,395,556 | 5,470,564 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $29.13 |
52-Week Low | $54.76 | $18.35 |
Typical Hold Time | 19 Days | 37 Days |
Enterprise Value | $8.60B | $11.53B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Gap trades at $23.36, down 1.81% for the day, with a bullish technical outlook from moving averages. The company shows strong profitability with a 43.26% gross margin and 8.14% net margin, supported by recent earnings beats. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B. Recent news highlights brand revitalization efforts, including music partnerships and board appointments, signaling strategic moves to engage customers.
The outlook is positive given low valuations (P/E 7.11, P/S 0.58) and analyst consensus target of $25.67, implying upside. Risks include reliance on Old Navy's turnaround and competitive pressures. Institutional activity is mixed, with some funds reducing stakes while others increase positions, reflecting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
